Excerpt from today very bearish article...kole?
The counter arguments that Amarin believers make is that patents will protect Vascepa. Not really. In this case, the patents primarily protect the manufacturing process - not the chemical itself. So, all GSK has to do in order to undercut Vascepa and once again reign supreme is find a creative way to purify fish oil to at least the same level as Vascepa and boom render Vascepa obsolete. Moreover, I can almost guarantee that GSK (and many other pharmas) will find a method that is faster and cheaper than Amarin's. So with this picture, what is Amarin's future?
haha... i love how you keep trying to take credit for an article. I'm sure illiteracy is frustrating. Let's start by writing a simple paragraph without phooking it up before trying to graduate to an article. :)